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In contrast to the relative ease of recognition and clarity of
treatment and prevention strategies in patients with symp-
tomatic coronary heart disease (CHD), a major problem of
detection, treatment, and prevention of CHD exists in the
large population who have no symptoms of heart disease yet
are at increased risk to develop CHD. Prevention of CHD
events in such asymptomatic individuals has traditionally
been called “primary prevention,” as it aims to prevent first
CHD events. Awaiting the clinical diagnosis of CHD
before beginning risk factor reduction will miss the oppor-
tunity to prevent a substantial number of CHD events, and
the American public will continue to suffer from a heavy
burden of CHD. This is particularly critical for people
whose first presentation is sudden cardiac death or disabil-
ity. Thus, the opportunity to prevent CHD events, rather
than be forced to treat the acute events and their future
consequences, has substantial appeal.
Risk reduction tailored to a patient’s specific risk has
evolved significantly over the past several decades and has
been shown to be effective when appropriately applied.
Similarly, guidelines based on risk assessment have ad-
vanced considerably. Clinicians have also become increas-
ingly familiar with the rationale for considering absolute risk
rather than relative risk, for calculating the “number needed
to treat,” and for understanding the importance of predict-
ing a wide range of different future clinical outcomes
(beyond mortality). Risk assessment was the central princi-
ple delineated at the 27th Bethesda Conference, entitled
“Matching the Intensity of Risk Factor Management With
the Hazard for Coronary Disease Events” (1). Despite this,
our ability to accurately determine risk remains limited,
especially for those asymptomatic people found to be in
intermediate risk ranges based on standard risk assessment
(Fig. 1). The latter group includes many individuals with
asymptomatic or “subclinical” atherosclerosis. This task
force report addresses the conceptual framework and back-
ground information necessary for understanding answers to
the overriding question for this 34th Bethesda Conference:
Can Atherosclerosis Imaging Techniques Improve the De-
tection of Patients at Risk for Ischemic Heart Disease?
Atherosclerosis imaging, including many different emerg-
ing technologies, may enhance the detection and treatment
of patients at risk for CHD. However, it is essential first to
address aspects of the problem, including its scope and
history, and to understand theoretical issues involving risk
prediction and contemporary nonimaging approaches.
Confusion exists over the common terminologies that
describe both clinical and laboratory diagnoses of conditions
related to coronary atherosclerosis. For the purpose of this
Bethesda Conference, we will use the term “coronary heart
disease” (CHD), defined as cardiac events or symptoms
related to myocardial ischemia and/or injury due, in the vast
majority of cases, to atherosclerosis. Such events include
unstable angina, myocardial infarction (MI), and sudden
death due to ischemic heart disease. Some studies cited also
include angina, or “new-onset” angina, as an “event.” It is
important to recognize that coronary atherosclerosis, isch-
emia, and events exist as a continuum. The former need not
necessarily lead to the latter, whereas the latter is virtually
always preceded by the presence of the former. The chal-
lenge, then, is not only to “detect” coronary atherosclerosis,
but also to “predict” which individuals, in whom coronary
atherosclerosis is detected, will progress to develop CHD
events.
Confusion also exists regarding the definition of “risk.”
Although a full discussion of risk is beyond the scope of this
report, it is important for the reader to understand that
“absolute” risk refers to that percentage chance that an event
will occur over a specific time period. “Relative” risk refers to
the ratio or odds of an individual’s risk compared either to
low risk or average risk (varies by study). Finally, when
considering risk or reviewing studies, one must remember to
ask: “Risk of what?” The risk of developing a single event
(such as cardiac death) will be quite different from the risk
of developing any one of a number of events (e.g., the typical
combined cardiac end point used in many studies), or the
risk of having atherosclerosis identified by an imaging
technique. Importantly, for consideration of issues raised in
subsequent task forces, it is critical to remember that the risk
of having atherosclerosis is very different from the risk of
actual events. In understanding risk, one must carefully
distinguish between diagnosis (e.g., presence of coronary
calcium or carotid intima-media thickening) and prognosis
(e.g., chance of developing an acute coronary syndrome).
SCOPE OF THE PROBLEM
Age-adjusted (CHD) mortality rates have declined by
approximately 50% since peaking in the U.S. between 1960
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and 1970. Nonetheless, by all measures, the burden of CHD
in the U.S. continues to be high. The decline in cardiovas-
cular disease is less in the subpopulations of lower socioeco-
nomic and certain ethnic groups and in geographic areas of
the country with poor socioeconomic profiles, in which the
burden of subclinical disease is substantial. Although age-
adjusted death rates have declined over the past two de-
cades, the absolute mortality rate from cardiovascular dis-
ease has not. Coronary heart disease accounts for over
one-half million deaths (1 out of every 5) in the U.S. yearly
(2). The lifetime risk of CHD after age 40 years has been
estimated at 49% for men and 32% for women (3). Even for
those who survive to age 70 years, lifetime risk for CHD has
been estimated at 35% for men and 24% for women (3).
Risk factors for CHD account for a large proportion of
the burden of heart disease in the U.S. today, suggesting
that risk-factor identification and risk-lowering treatment
could postpone or prevent the majority of CHD events.
This is best demonstrated by studying CHD risk in persons
lacking any of the major CHD risk factors (as the reference
group). In a report from several U.S. cohorts, age-adjusted
CHD mortality rates per 100,000 person-years among men
with the lowest risk factor values at baseline ranged from
rates of 2 to 6 in men 18 to 39 years of age and from 44 to
88 in men ages 40 to 59. Lowest risk status was defined as
having all of the following favorable risk factor traits at
baseline: serum cholesterol less than 200 mg/dl, systolic
blood pressure (SBP) less than or equal to 120 mm Hg,
diastolic blood pressure (DBP) less than or equal to 80 mm
Hg, noncurrent smoker, no history of diagnosed diabetes,
no previously diagnosed MI or hypertension, and no base-
line electrocardiogram (ECG) abnormality. Estimated
CHD mortality rates for those with at least one major risk
factor is substantially increased in both women (approxi-
mately four-fold) and men (approximately five- to eight-
fold) (4).
Healthy life habits can also define members of the
population who are at low risk for CHD. In a report from
the Nurses’ Health Study (5), relative risk for CHD events
(fatal and nonfatal) was 82% lower among nonsmoking,
non-obese (body mass index less than 25) women who
engaged in more than 30 min of moderate-to-vigorous
exercise/day, consumed at least half a drink of an alcoholic
beverage daily, and scored in the highest 40% of the cohort
for consumption of a diet high in cereal fiber, marine n-3
fatty acids, and folate, with a high ratio of polyunsaturated
Figure 1. Data from the Framingham Heart Study experience. Much of the middle-aged population has a low to intermediate risk for hard CHD
(myocardial infarction or CHD death). Even up to age 80 years, more than three-quarters of women experience a 10-year risk of CHD that falls below
10%. The risks are higher for men, and by age 60 the majority of men are at intermediate (10% to 20% per 10 years) or high risk (greater than 20% per
10 years) for CHD. Figure courtesy Peter W. F. Wilson, MD, Framingham Heart Study (unpublished data).
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to saturated fat and low in transfat and glycemic load (5).
Thus, optimal risk-factor status confers a very low risk of
CHD, an important concept as newer detection modalities
are considered. Unfortunately, the prevalence of optimal
risk-factor status in developed countries is low (about 10%
or less of adults). Thus, among the many individuals with
coronary risk factors who are at increased risk of developing
incident CHD, the challenge is to identify accurately those
who ultimately will develop CHD. Compounding the high
prevalence of risk factors and unhealthy life habits is the fact
that risk factors are inadequately assessed and treated (6).
PRESENTATION OF CHD IN THE POPULATION
Understanding the demographics of CHD is critical for the
evaluation of issues involving the early detection of the
disease. Many factors influence how patients present with
CHD. A large majority of sudden cardiac deaths occurring
outside the hospital are in individuals without preceding
signs or symptoms of disease. The presentation of CHD is
also affected by nonbiologic factors such as socioeconomic
status and the attributes of the care system itself. Approx-
imately 12.6 million Americans have CHD manifested as
MI, angina pectoris, or both (2). For 1999, the overall CHD
death rate in the U.S. was 195.6 per 100,000 population. Of
the estimated 1.1 million Americans who experience MI
annually, 650,000 are first-time events, and 450,000 are
recurrences (2). More than 45% of these events are fatal,
most from cardiac arrest associated with ventricular fibril-
lation. Approximately 250,000 people a year die of CHD
without being hospitalized. Approximately 400,000 new
cases of stable angina and about 150,000 new cases of
unstable angina occur annually. The National Center for
Health Statistics reported in 1996 that nearly 60% of those
patients who were admitted with a diagnosis of unstable
angina were over 65 years of age, and 46% of patients of all
ages were women (7). Time trends suggest that the inci-
dence of CHD and stroke, which declined through the
1970s and 1980s, has peaked and the actual prevalence rates
have begun to increase as our population ages. Paradoxi-
cally, improvements in care, by leading to improvements in
survival, appear to be resulting in greater numbers of CHD
events overall. As this occurs, the imperative to predict these
events with more accuracy grows proportionally.
DETECTION
Despite many available risk assessment approaches, a sub-
stantial gap remains in the detection of asymptomatic
individuals who ultimately develop CHD. The Framing-
ham and European risk scores, and more recently the
Framingham-based National Cholesterol Education
Program-Adult Treatment Panel (NCEP-ATP III) risk
score (8), all emphasize the classic CHD risk factors
incorporated into useful predictive models. However, this
standard CHD, “evidence based,” multiple risk factor as-
sessment approach is only moderately accurate for the
prediction of short- and long-term risk of manifesting a
major coronary artery event, particularly an event such as
sudden death, in healthy populations (9,10). It is uncertain
whether the addition of newly emphasized risk markers will
sufficiently assist in the quantitative assessment of CHD risk
to allow adequate precision for optimal matching of the
intensity of management to the level of risk.
A potentially important discrepancy has arisen in our
understanding of the role of conventional risk factors and
atherosclerosis compared to the development of CHD
events. Although considerable data suggest that there is a
very low event rate in people with extremely low risk
profiles, the presence of risk factors in studies of subclinical
atherosclerosis detected by imaging techniques appears to
explain the presence and extent of disease less completely.
For example, in a study of over 600 army personnel without
known CHD, of the traditional risk factors evaluated only
low-density lipoprotein (LDL) cholesterol was indepen-
dently associated with coronary artery calcification by
electron-beam computed tomography (EBCT) (11). In that
study the relationship between coronary calcium and the
Framingham risk score was positive but weak. Data from
the Cardiovascular Health Study did demonstrate that
traditional risk factors were determinants of subclinical
disease, but appeared to have a smaller association with
clinical disease once subclinical disease developed (12).
Finally, in recent work from the Framingham Heart Study,
the global risk score did correlate with the presence of
subclinical aortic atherosclerosis, but only weakly (r  0.20)
(13). If confirmed, this apparent difference in the relation-
ship between risk factors and clinical versus subclinical
disease might have important implications in the role of
subclinical detection and risk prediction. As will become
evident throughout this Bethesda Conference, the relation-
ship between the demonstration of atherosclerosis has a
variable, and often uncertain, relationship to the develop-
ment of future CHD events.
An understanding of certain principles of screening needs
to precede any evaluation of screening techniques. Accord-
ingly, we review Bayes’ theorem and use exercise stress
testing to illuminate issues of predictive accuracy and pretest
probability.
Bayes’ theorem. The predictive value of any test depends
on the sensitivity and specificity of the test, and on the
prevalence of the condition in the population being tested.
This notion, based on Bayes’ theorem, has been extensively
explored and discussed in the field of exercise stress testing.
In simple terms, the greater the likelihood that the condi-
tion being screened for is present in an individual or in the
population (pretest probability), the greater the validity of a
positive test and likelihood that this is a true positive. Thus,
the problem with using a test in any population where there
is a low likelihood of the condition being present is that a
positive result has limited value (i.e., it is more likely to be
a false positive). Figure 2 demonstrates how even a test with
high sensitivity and specificity will yield a low predictive
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accuracy in a population with low disease prevalence.
Similarly, one must remember that in populations at very
high risk, a negative test result is more likely to be a false
negative. Because correct treatment depends upon accurate
identification of both true positive and true negatives, an
understanding of these concepts is critical for decisions
about the use of any new testing modality. By reviewing the
paradigm of stress testing, as follows, we can apply these
lessons to the consideration of testing modalities that are the
subject of this Bethesda Conference.
Exercise stress testing. Various noninvasive tests are avail-
able to identify evidence of stress-induced myocardial isch-
emia in patients with symptomatic or asymptomatic ob-
structive coronary artery disease. Exercise ECG testing has
been most extensively studied, and decision-making criteria
have been developed based on these data. Compared to a
positive test in a patient with ischemic symptoms, a positive
exercise stress test in an asymptomatic person has quite
different implications, based on the generally lower pretest
probability of inducible myocardial ischemia. As shown
repeatedly in clinical studies of exercise stress testing in
unselected asymptomatic people, the majority of positive
stress tests are false positives. Conversely, exercise testing in
middle-aged men with elevated levels of traditional risk
factors carries independent predictive power for major
coronary events. The same predictive power does not hold
for young adults and middle-aged or older women, even
with risk factors, in whom disease prevalence is lower.
Despite that, the absolute risk of a cardiac event is quite low
in those patients with positive stress tests who have no risk
factors, while the presence of at least one risk factor
associated with abnormalities on stress testing is associated
with substantial (30-fold) higher five-year risk compared to
those with no risk factors present (14,15). Thus, despite the
markedly higher relative risk, the absolute likelihood of
event remains low, and because of the low baseline risk, the
chance of a false positive test is high.
The impact of this problem of low pretest probability is
considerable. Large studies suggest that the positive predic-
tive value of exercise ECG testing in asymptomatic people
is less than 10% for predicting “hard” CHD events (cardiac
death and MI) (16,17). The addition of myocardial imaging
does not greatly improve predictive accuracy unless patients
are selected because of the presence of one or more risk
factors (18). Hence, the expense of the test and its low yield
of positive outcomes make it unsuitable for routine risk
assessment in asymptomatic individuals, except, perhaps,
among those at high baseline risk (high pretest probability),
a lesson that must be remembered when considering other
noninvasive tests for the detection of cardiovascular risk.
The challenge facing any screening test that has less than
perfect performance when applied to a low prevalence
population is illustrated in Figure 3. In this example, an
analogy is made using data from Hachamovitch et al. (19),
which quantified the incremental value of single-photon
emission computed tomography (SPECT) perfusion imag-
ing over Duke treadmill score for predicting cardiac events
in a symptomatic population. Figure 3 demonstrates that
the more sensitive test, the SPECT, predicted a greater
number of events (Fig. 3A), compared to the less sensitive
Duke treadmill score. However, when examined according
to the absolute number of events, subjects with low/normal
and intermediate/mild test results actually accounted for the
majority of events (Fig. 3B). This problem is amplified in a
low prevalence population. Although this concept does not
undermine the importance of screening a population, it does
illustrate the reality that, with any less than perfect test, a
majority of subjects at true risk may still go undetected.
Other tests for CHD risk must be evaluated in low risk
populations, and predictive accuracy must be measured in
these low risk populations, before such tests can be recom-
mended for risk assessment.
ATHEROSCLEROSIS DETECTION FROM OTHER TESTS
Other approaches to cardiovascular risk prediction have
been considered because exercise stress testing cannot be
regarded as an appropriate means of identifying a large pool
of asymptomatic high-risk people. As discussed in later
Task Force documents, several noninvasive tests are now
available that directly detect atherosclerosis in different
vascular beds. Because atherosclerosis is a generalized ma-
crovascular disease, lesions in one vascular territory predict
disease in other arterial regions. Similar risk factors are
present among patients with coronary, peripheral, and
Figure 2. Influence of disease prevalence on predictive accuracy of a typical
diagnostic strategy. When used in a population with low disease preva-
lence, such as an asymptomatic population undergoing cardiovascular
screening, even a test with excellent sensitivity (Sens) and specificity (Spec)
will yield a poor positive predictive accuracy owing to a larger number of
false-positive (FP) than true-positive (TP) results. CAD  coronary artery
disease. Reprinted with permission from Gheorghiade and Bonow (43).
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carotid atherosclerosis. Of particular importance is evidence
that disease in noncoronary arteries is a powerful predictor
of CHD mortality. In fact, ATP III has termed aortic,
peripheral, and carotid artery disease as “Coronary Heart
Disease Equivalents” because the level of CHD risk and
CHD event rates associated with these conditions is ap-
proximately equivalent to the level of risk seen in stable
CHD (8). The rate of CHD events in persons with
atherosclerotic vascular disease in other territories is similar
to event rates in patients with known CHD. Thus, screen-
ing for atherosclerosis in other vascular regions has been
considered for CHD risk evaluation.
Nonimaging detection of CHD risk. Our understanding
of the clinical manifestations of atherosclerosis derives from
the study of pathophysiology, epidemiology, and from
clinical trials, and has added substantially to our ability to
identify and modify risks for CHD. Nonetheless, important
limitations exists in our ability to precisely identify individ-
uals who should be targeted for aggressive risk modifying
interventions. It is thus appropriate to review current
clinically available approaches to stratify risk of CHD.
History and physical examination. Although often under-
emphasized in today’s world of advanced technology, the
history and physical examination continue to play an im-
portant role in assessing the risk for CHD in both asymp-
tomatic and symptomatic subjects. The history identifies
important components, including the presence or absence of
cardiac symptoms, known major risk factors for CHD, and
comorbid conditions. The physical examination is comple-
mentary to the history and may enhance the assessment of
the presence of vascular disease and CHD risk factors.
Although history is very sensitive for the detection of CHD,
the physical examination is not. In a two-year study of 630
patients, the history correctly detected the diagnosis in
Figure 3. (A) The event rate (cardiac death [CD] or nonfatal myocardial infarction [MI] percent per year) is depicted on the y-axis as a function of test
result, on the x-axis (DTS  Duke treadmill score as low, intermediate, or high risk score; single-photon emission computed tomography [SPECT]
imaging as normal, mildly abnormal, or severely abnormal). For both tests, event rates with a low risk (DTS) or normal (SPECT) result are low: 0.9% per
year for DTS, 0.4% per year for SPECT. (B) The data from Hachamovitch et al. (19) are reconfigured to demonstrate the proportion of all patients who
had events (y-axis) for each given test result (x-axis). The majority of patients experiencing events (approximately 85%) had a low- or intermediate-risk DTS,
whereas a smaller though not inconsiderable proportion of events occurred in patients with a normal or mildly abnormal SPECT (approximately 50%).
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two-thirds of the patients and physical examination in just
one-fourth (20).
Traditional risk factors (Table 1). Ever since the initia-
tion of the Framingham Heart Study more than 50 years
ago, our knowledge of CHD risk and the benefit of risk
modification has grown considerably. In fact, the term “risk
factor” was coined by an early Framingham investigator
(21). We now identify both “traditional” risk factors and
newer “novel” risk factors (Table 2). Although the identifi-
cation of traditional risk factors does not identify all CHD
risk, the absence of all major risk factors does identify those
individuals at very low risk. For high-risk patients, the
major traditional risk factors account for between 50% and
80% of subsequent cardiovascular events (15,22).
IDENTIFYING THE HIGH-RISK
ASYMPTOMATIC PATIENT: GLOBAL RISK ASSESSMENT
Mathematical models incorporating assessment of major
CHD risk factors have been used to predict general levels of
risk (e.g., low, intermediate, or high) and to estimate the
yearly percentage risk (absolute risk) of future events
(9,10,23). Estimates or scores derived from these models
(Table 2) are now commonly known as “global” risk scores.
Formal endorsement of global risk scoring to identify higher
risk individuals has come from the American Heart Asso-
ciation (AHA), the American College of Cardiology
(ACC), the European Society of Cardiology, and most
recently ATP III (8,23). As national guidelines have ad-
vanced, clinicians have been presented with increasingly
more sophisticated ways to assess risk (23,24). Both ATP II
and Joint National Committee (JNC) VI published in 1993
and 1997, respectively, used “risk factor counting.” The
most recent European and U.S. lipid guidelines (ATP III)
use a score derived from the Framingham Heart Study to
estimate 10-year risk of having a cardiac event to help divide
patients into low, intermediate, and high risk subgroups,
and specifies different intensities of treatment for each
subgroup.
A modification to this subgrouping has recently been
suggested to improve CHD risk assessment in asymptom-
atic people (10). This approach considers a less than 0.6%
per year (less than 6% over 10 years) risk for coronary events
as “low-risk.” Such individuals generally are free of any
major CHD risk factors. A 0.6% to 2.0% per year (6% to
20% over 10 years) risk is termed “intermediate risk,” and
includes most individuals with at least one major positive
CHD risk factor. Those with greater than or equal to 2.0%
per year (greater than or equal to 20% over 10 years) risk are
“high-risk” as they have a level of risk equivalent to patients
with stable established CHD. We have adopted these
definitions of levels of risk for this Bethesda Conference.
Huge numbers of people in the U.S. would appear to be
candidates for risk factor reduction efforts and for public
health initiatives (Fig. 1).
The most recent “global risk score” version (8) includes
the following variables: age, gender, total cholesterol, high-
density lipoprotein (HDL) cholesterol, smoking status,
SBP, and hypertension treatment (yes/no). The individual’s
germane CHD health information is entered either into a
score sheet, computer, Web page, or palm pilot, and an
absolute yearly risk (percent chance of a major coronary
event) or 10-year risk is calculated. The current version
estimates the likelihood of MI or cardiac death (“hard
events”), as these end points are well validated. Diabetes is
not part of the ATP III risk algorithm, as the diagnosis of
adult onset diabetes mellitus is itself considered a CHD risk
equivalent (high risk even without other risk factors or
clinically evident CHD), thus having a 10-year risk of
approximately 20%.
Can global risk assessment sufficiently identify individuals
at risk for cardiovascular events and focus preventive treat-
ment appropriately? Is the test sufficiently sensitive to detect
the majority of people at risk and specific enough to exclude
those at lower risk? Is a staged testing strategy more
Table 2. Examples of Approaches to Risk Assessment With
Multiple Coronary Heart Disease Risk Factors
NCEP: ATP I and II—Risk-factor counting; ATP III—Global Risk
European Societies of Cardiology, Atherosclerosis, and Hypertension
Framingham Risk Score
British Regional Heart Study (BRHS) Risk Score
Sheffield Coronary Risk Tables
GREAT (General Rule to Enable Atheroma Treatment)
Munster Heart Study (PROCAM) Risk Score
Dundee Coronary Risk Disc
National Heart Foundation of New Zealand Guidelines
West of Scotland Cardiovascular Event Reduction Tool (CERT)
Adapted from Greenland P, et al. (10).
Table 1. Risk Factors for CHD
Major independent risk factors
Cigarette smoking
Elevated blood pressure
Elevated serum total and LDL cholesterol
Low serum HDL cholesterol
Diabetes mellitus
Advancing age
Other (predisposing) risk factors
Obesity
Abdominal obesity
Physical inactivity
Family history of premature CHD
Ethnic characteristics
Psychosocial factors
Conditional risk factors
Elevated serum triglycerides
Small LDL particles
Elevated serum homocysteine
Elevated serum lipoprotein(a)
Prothrombotic factors (e.g., fibrinogen)
Inflammatory markers (e.g., C-reactive protein)
CHD  coronary heart disease; HDL  high-density lipoprotein; LDL 
low-density lipoprotein. Adapted from Grundy (25).
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appropriate than using a single testing strategy for all
patients, regardless of risk-factor levels, global risk assess-
ment, or other means of sorting patients prior to further
testing? Unfortunately, these questions remain largely un-
answered, and they should be the focus of future investiga-
tions.
Greenland et al. (10) have recently suggested an approach
to the office-based assessment of asymptomatic patients
centered on global risk assessment. This approach begins by
utilizing the Framingham risk scoring method to estimate
absolute coronary risk. Subsequently, individuals are strati-
fied into low risk (less than 6% 10-year absolute risk), an
intermediate risk group (risk 6% to 20% per 10 years), and
high-risk group (risk greater than 20% over 10 years). They
estimate that of the U.S. adult population, 35% fall into the
low-risk group, 40% into the intermediate group, and 25%
into the highest-risk group. This compares favorably with
proportional risk estimates for men developed by Wilson for
this Bethesda Conference, but overestimates the proportion
of women in intermediate and high-risk groups (Figs. 1a
and 1b). Patients at low risk are easily categorized, and they
require primarily reassurance and advice regarding healthy
lifestyles, whereas the high-risk group (risk greater than
20% for 10 years) will benefit from aggressive risk factor
reduction. As so often is true in medicine, the intermediate
group represents the greatest challenge for treatment deci-
sions. However, even in the high-risk category, several
issues can be raised:
● Are there high-risk group individuals who should be
submitted to further risk testing to assess interventional
options beyond risk factor modification? How can these
subjects be identified?
● If further CHD risk assessment identifies significant
abnormalities, can the further testing refine the indica-
tions for an intervention such as angiography or coronary
artery revascularization?
Substantial questions remain for the large group of people at
intermediate risk.
● Which patients in this group should or should not be
recommended for drug treatment or other interventional
therapies?
● How should patients within the intermediate group be
best stratified with additional testing?
NOVEL, PREDISPOSING, AND
CONDITIONAL RISK FACTORS
“Novel” risk factors (Table 1) have received considerable
attention in the published reports, both for their role in
advancing our understanding of atherosclerotic pathophys-
iology and for their possible ability to improve identification
of high-risk individuals. Because of the apparent ability of
certain of these factors to influence the effects of the known
major risk factors, Grundy (25) has termed some of these as
“conditional” risk factors. They can be divided into infec-
tion/inflammatory markers and serum markers.
Infection/inflammatory markers. Markers of inflamma-
tion such as high sensitivity C-reactive protein (CRP)
elevated white blood cell count (WBC), and positive serol-
ogy for bacterial and/or viral infections have all been
reported to be associated with an increased incidence of
CHD events (26,27). Prospective studies of CRP have
shown elevated levels to be associated with two- to four-fold
higher risk of different cardiovascular end points (26–30).
In the Nurses’ Health Study (29), CRP was shown to
improve cardiovascular risk prediction significantly when
added to total and HDL cholesterol evaluation. Ridker (30)
has proposed that increasing CRP levels can add to the
predictive value of lipid assessment. Data from the Wom-
en’s Health Study show an incremental prognostic value to
CRP when added to the Framingham risk score (31).
Nevertheless, there remains considerable debate regarding
the use of CRP as a risk marker because of difficulty
identifying a “cut point” for prognostic significance of this
marker and concerns about reliability and accuracy (32,33).
The utility of CRP testing across different ethnic groups is
also unknown. Thus, routine measurement of CRP is not
currently recommended by the American Heart Association
(34).
Serum markers. An elevated homocysteine level has been
shown in many but not all studies to be associated with an
increased risk of CHD (35). The data do not yet suggest
that routine measurement of homocysteine would be bene-
ficial in risk assessment. Many additional serum lipid
markers, including small dense LDL, apolipoproteins A1
and B, and lipoprotein (a), have been related to increases in
CHD risk. Owing to insufficient prospective data, variabil-
ity of and access to testing, and questions of cost-
effectiveness, these markers have not yet been found to add
value to CHD risk assessment beyond those identified
under traditional risk factor assessments (22,34).
An illustrative comparison of the relative risk of future
events among women for the most commonly used novel
markers and standard lipids is shown in Figure 4 (32).
Considerable overlap exists in confidence intervals, which
are quite large. Thus, although likely useful for comparing
populations or groups, one can see that the precision of a
risk estimate for any of the novel markers in an individual
patient is likely to be poor. Furthermore, the estimates
shown in Figure 4 compare only the highest risk quartile
with the bottom quartile—again useful for understanding a
population but virtually useless for an individual, whose
individual risk lies somewhere along a continuous spectrum.
Figure 5 demonstrates how a mathematical model based
on factors similar to those employed in the Framingham
risk-scoring system can improve upon risk prediction when
compared to simple risk-factor counting, as assessed by
receiver operating characteristic (ROC) curves. Estimation
of risk by the Framingham risk score, or any similarly
derived regression equations, can be seen to represent a “low
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bar” on the risk-prediction ladder. This tool is widely
accessible, easily used, and almost cost-free. The evidence-
base for using this approach is robust. Many of the potential
tools available to help further risk stratify those within this
group, such as CRP measurements, coronary calcium scor-
ing, or carotid ultrasound for intima-medial thickness
(IMT) measurement, have been the subject of considerable
additional attention, as discussed in this Bethesda Confer-
ence document. Improvements in risk estimation should be
viewed in the context of their relative benefit when added to
the Framingham risk score (or a similar algorithm).
CURRENT BARRIERS TO RISK ASSESSMENT
Because CHD is the leading cause of morbidity and
mortality in the U.S., and because as much as half of the
mortality from this disease occurs in previously asymptom-
atic individuals, the principal barrier to identifying at-risk
asymptomatic individuals is the sheer magnitude of the
problem. The first challenge that should be addressed, well
beyond the scope of this Bethesda Conference, involves the
need for a greater understanding and awareness of the
potential risk for CHD by both our adult population and by
medical professionals. Awareness is a population issue that
no screening approach can address, no matter how optimal.
Inadequate adherence to medical and lifestyle interventions
has been increasingly recognized as an important medical
problem. Principles embodied in approaches to improve
adherence with therapies may also be applied to understand-
ing the adherence barriers in risk screening and prediction.
Such barriers can be divided into three categories: those that
exist: 1) for patients in the population, 2) for physicians and
other caregivers, and 3) for the medical system itself.
Although a detailed discussion of these issues is beyond the
scope of this report, several principles can be noted:
● Awareness—individuals and professionals must be aware
of the important concept that the level of risk interven-
tion (and subsequent benefit) depends upon identifying
those at highest risk.
● The public and professionals must have access to under-
standable risk assessing strategies and technologies. A
recent study (36) suggests that routine calculation of
CHD risk in primary care settings is hindered by poor
availability of risk factor data and by inappropriate and
consequently inaccurate use of risk-calculation tools.
● Risk assessment modalities need to be valid and repro-
ducible. The validity across different populations, ages,
genders, and ethnic backgrounds must be understood.
Another important barrier is the absence of prospective
data demonstrating added benefit when additional risk
assessment is added to global risk scoring. Unfortunately, to
date, most studies evaluate emerging laboratory tests and
technologies compared to baseline population estimates, or
compared to other risk assessment strategies. Further bar-
riers in risk assessment include aspects of understanding risk
itself, specifically “risk of what?” An ideal hierarchy might
be proposed, such as 1) identify those at risk for sudden
cardiac death, then 2) those at risk for MI or stroke,
Figure 4. Comparison of the magnitude of relative risk of future cardiovascular events associated with abnormal values of different risk factors or
combination of risk factors. The data are derived from initially healthy women in the Nurses’ Health Study. In each case, relative risk is shown (black box)
for individuals in the top versus the bottom quartile for each factor, 95% confidence intervals are shown by the horizontal lines. (Ridker [30]).
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followed by 3) individuals at risk for angina or claudication.
However, in assessing risk, it is clear that individual tools
and technologies will not be equally accurate with respect to
predicting different end points. For example, identification
of extensive carotid atherosclerosis by carotid ultrasound is
presumably more likely to be predictive of future stroke than
would be true by the identification of coronary calcium by
EBCT. Both techniques have been shown to be helpful in
predicting of future coronary events. When comparing risk
assessment strategies, comparisons will need to be made for
equivalent end points.
Measurement of risk itself is also problematic. Changes in
absolute risk (the probability of developing an event over a
finite period of time) must be the critical starting point for
risk assessment and evaluation of risk reduction strategies.
However, absolute risk increases are often quite small, as is
absolute risk reduction, even for established risk lowering
therapies. Thus, relative risk and relative risk reduction are
often considered (relative risk is the ratio of absolute risk in
a patient undergoing the risk assessment compared to risk
level for a person at average or at low levels of risk). Relative
risk is useful for comparing different techniques or inter-
ventions. Finally, the duration of risk prediction is impor-
tant. Some approaches for risk assessment are likely to be
more useful for near-term prediction of events (e.g., stress
testing), whereas others are more likely to be useful in
assessing risk over the long term or life of an individual (e.g.,
LDL cholesterol level).
The size of the population studied in evaluation of risk
prediction is also of critical importance. Many studies have
employed statistically inadequate sample sizes. Because
CHD events are relatively unusual in low-risk and even in
intermediate-risk populations, large populations are re-
quired to accurately assess the usefulness of any risk predic-
tion strategy. Finally, as this field moves forward, the
clinician and investigator must keep in mind several factors
in the evaluation of any diagnostic or screening test, beyond
the reported accuracy and predictive value of the test:
● Is there a referral bias?
● Is the reference population valid?
● How are uninterpretable tests handled in the analysis?
● Is the test population excessively homogeneous?
● Is the test practical to put into practice?
● Is it practical to put the results of the test into practice?
● What are the down-stream costs and the cost-
effectiveness of the test?
THE DETECTION GAP
Magnitude of the detection gap. There is no debate that
a detection gap exists. The size of this gap can only be
estimated by orders of magnitude, in part because we cannot
count those individuals who remain undetected. For exam-
Figure 5. Receiver operating characteristic (ROC) curves for screening guidelines including the first and second National Cholesterol Education Programs
(NCEP I and II) and the Canadian Consensus Conference on Cholesterol (CCCC). The 45° line (broken line) represents a nondiscriminating test where
the true-positive rate equals the false-positive rate. The NCEP II guidelines performed the best with an area ( SD) beneath the curve of 0.74  0.03,
followed by the NCEP I (0.72  0.03), and the CCCC (0.70  0.03). The NCEP II guidelines also performed significantly (p  0.03) better than the
NCEP I in predicting coronary deaths. The computer risk model had an area of 0.85  0.02 and was a significantly (p  0.03) better discriminator than
any of the expert guidelines (Grover et al. [44]).
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ple, ATP III estimates (8) that approximately 36 million
individuals require drug treatment for elevated LDL cho-
lesterol levels, others suggest the number could be more
(37). Yet, only 10 million to 15 million Americans are
currently receiving lipid-lowering drugs. The last national
blood pressure guideline report (38) estimated that about
one-third of hypertensives in the U.S. population were
undetected. With the estimated number of people with
hypertension in this country at 50 million, that leaves very
large numbers at risk yet undetected. Nearly half a million
sudden deaths (most with CHD) and over a million MIs
occur yearly in the U.S. Thus, the size of the at-risk
population could also be estimated as follows: high-risk
individuals have an approximate risk per year of 2% or
greater; if there are 650,000 sudden primary deaths and MIs
annually, the total at risk population would equal 30 million
to 37 million or more. The number receiving comprehensive
risk- lowering therapies is clearly vastly lower than that sum.
Effective application. Despite opportunities to refine risk
assessment in order to focus on and reduce risk more
effectively, there exists the larger problem of effectively
applying recommendations to patients. Various guidelines
have been published by the ACC/AHA for both primary
and secondary prevention and have been recently updated.
Guidelines have also been published clarifying the focus of
risk assessment and guiding clinical intervention.
Unfortunately, however, it has been shown that, although
clinicians may be aware of guidelines, such guidelines are
not effectively or routinely applied to practice. Pearson et al.
(39) demonstrated in a group of medical practices that
provider awareness of NCEP guidelines was quite high
(95%). However, the number of patients within those
practices treated to goal levels was unacceptably low (18%).
Fonarow et al. (40), using National Registry of Myocardial
Infarction (NRMI)-3 data, reported that only 31.7% of
patients (138,000) with acute MI were discharged on
lipid-lowering therapy. They also demonstrated that a
program of hospital-based, organized patient and provider
education resulted in a significant improvement of utiliza-
tion rates of recommended drugs (41). This is an example of
how systematic interventions can improve the “treatment
gap”; similar interventions need to be developed and tested
to improve the “detection gap.”
Potential for incremental information to improve predic-
tion of CHD events. As already reviewed, numerous
possible approaches are now available to improve risk
assessment, thereby potentially useful to decrease the detec-
tion gap. Many of these are widely available, relatively valid,
and safe. Our understanding of their cost effectiveness is
evolving and will be discussed later in this Bethesda Con-
ference. Previous guidelines and scientific advisories have
encouraged use of newer approaches, but advice generally
has been relatively nonspecific. For example, the AHA
Prevention V Conference suggested “more routine use of
office-based risk assessment” (15). Further specific refine-
ment of this advice is clearly needed. The perspective offered
by Greenland, Smith, and Grundy (10) advances this
general approach. Figure 6 (taken from their report) is
illustrative. It demonstrates how additional test results can
either substantially increase or decrease the probability
estimate of a future CHD event by increasing the chance
that a positive result is a true positive, or that a negative
result is a true negative. Figure 6 also integrates the concept,
derived from the Bayes’ theorem discussed above, that the
post-test probability of a CHD event is markedly influenced
by the prevalence of such events in a population (pretest
probability). Modifications in risk prediction, such as this,
could potentially better target risk reducing interventions to
individual patients.
Conclusions. Global risk scoring should be viewed as the
cornerstone of cardiac risk evaluation. For both patient and
provider, it has the potential to enhance the understanding
of cardiovascular risk for an individual, and improve patient
and provider application and adherence to evidence-based
risk-reducing interventions. Atherosclerosis imaging, as
subsequently reviewed in this Bethesda Conference, has
considerable potential to improve risk assessment, although
the appropriate use of such testing should anchor on
principles from the U.S. Preventive Service Task Force,
including demonstration that the tests are accurate, reliable,
Figure 6. In this example, pretest probability is estimated by standard
coronary heart disease (CHD) risk factor measurements in a multivariable
model, such as the Framingham risk score, to predict a future event
(dashed line). The solid and dotted lines represent curves generated,
depending on whether the subsequent test result is positive (solid line) or
negative (dotted line). The arrows represent how a patient with a 15%
pre-test probability would have markedly different post-test probabilities
depending on whether the additional noninvasive test was positive or
negative. In this example, an individual who undergoes a screening
evaluation that suggests a 15% chance of having a CHD event in the next
10 years undergoes a second test, and the 15% prediction is modified
upward and becomes more than 35% if the test is positive, or is modified
downward and becomes less than 5% if the second test is negative. This
figure demonstrates how additional test results can either substantially
increase or decrease the probability estimate of a future CHD event by
increasing the chance that a positive result is a true positive, or that a
negative result is a true negative. (Adapted from Greenland et al. [10]).
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and beneficial (32,42). Investigators and clinicians should
adopt new diagnostic or prognostic testing based on the
same firmly established, evidence-based standards used for
adoption of new therapies on procedures. Furthermore, it
remains clear that even optimally applied global risk assess-
ment would continue to lead to a gap in our ability to
predict those individuals at greatest risk for developing
CHD events. The magnitude of this gap, although not
precisely quantifiable, is likely very large.
FUTURE DIRECTIONS
1. A detection gap in CHD prognosis exists. The precise
size of this gap is unknown, but is likely substantial.
Prospective study is needed to identify its magnitude and
implications.
2. Current CHD risk screening tools are imperfect and
imperfectly applied. Because these are not optimally
accurate, opportunities exist (e.g., with newer biologic
markers and/or atherosclerosis imaging) for their refine-
ment. Current CHD risk-screening tools should be the
subject of effectiveness testing. Greater commitment is
needed toward funding such research initiatives.
3. Based upon the Bayes’ theorem, the application of
atherosclerosis imaging is theoretically best suited to
intermediate risk populations. Before this application
becomes practice there is need for a greater body of
supporting evidence in which the incremental benefit of
obtaining such information is demonstrated.
4. Concomitant with efforts to utilize atherosclerosis imag-
ing for more accurate detection of CHD risk, the
community of cardiologists must champion CHD pre-
vention, beginning by fully translating existing data on
effective risk-screening and interventions into practice.
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Atherosclerosis is composed of cellular and acellular
elements that combine to form a variety of plaque
types (Table 1, Fig. 1). With respect to atheroscler-
osis imaging, four plaque histologic characteristics are
considered in this Task Force report: necrotic core,
fibrous cap, calcium, and inflammatory activity. The
relative prevalence of these components depends on
the degree of stenosis, the clinical coronary heart dis-
ease syndrome, and nonlocal factors including the pa-
tient’s gender and traditional and nontraditional risk
factors.
COMPONENTS OF ATHEROSCLEROSIS THAT
FORM TARGETS FOR ATHEROSCLEROSIS IMAGING
Several studies (1–4) have reported the relationship between
the following types of plaque components and degree of
stenosis.
Necrotic core. A necrotic core is present in approxi-
mately 25% of plaques with less than 50% cross-sectional
stenosis, and this increases in prevalence with increasing
stenosis severity. Above 70% cross-sectional luminal
narrowing, about 75% of plaques will demonstrate a
necrotic core.
Fibrous cap. Fibrous cap atheromas are defined as
plaques with a well-defined lipid core covered by a
fibrous cap, which may be relatively acellular (made
of dense collagen) or may be rich in smooth cells. No
data in autopsy studies are available regarding the
prevalence of fibrous caps of various thickness. Sten-
osis severity is directly related to the proportion of
dense fibrous tissue (type I collagen) in the fibrous cap,
and inversely related to smooth-muscle-cell–rich areas
(2– 4).
Calcium. The presence of calcium is strongly correlated
with stenosis severity (3–6) (Fig. 2) and is modulated by
age. As age advances, the mean percent calcified area
increases both for plaques with moderate (greater than or
equal to 50% to less than 75% cross-sectional area) luminal
narrowing and severe (75% to 90% cross-sectional luminal
area) narrowing (5). Importantly, a thrombotic, recanalized
total occlusion may be devoid of calcification. The incidence
of calcification in total occlusions may be partly a function of
lesion age (7).
Inflammatory activity. Inflammation, both of the intima
and adventitia, increases in prevalence with increasing
percent stenosis (1).
1874 Burke and Virmani et al. JACC Vol. 41, No. 11, 2003
Task Force #2—Pathologic Basis for New Atherosclerosis Imaging Techniques June 4, 2003:1855–917
